Brief: Ventyx Biosciences Q4 Operating Expenses USD 50.346 Million
27/02/2024 21:01
Feb 27 (Reuters) - Ventyx Biosciences Q4 net income USD -46.753 million
Recent news on Ventyx Biosciences
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (updated)
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
Deals of the day-Mergers and acquisitions